All GLG News Analyses Filed Under: Infectious Disease

John Ansell, MBADirectorJohn Ansell Consultancy

A triple combination for H1N1: good in principle

October 30, 2009

Analysis of:  Triple-combo Drug Shows Promise Against Antiviral Resistant H1N1 | www.medicalnewstoday.com

The principle behind Adamas’s triple combination development for influenza is a good one. There is clearly a need for improved treatments, as the latest wave of swine flu is now showing. Oseltamivir (Tamiflu) and ribavirin are reasonable drugs to select but the third component, amantadine, may prove...

Which Combination of Drugs for Influenza?

October 29, 2009

Analysis by:GLG Expert Contributor

Analysis of:  Triple-combo Drug Shows Promise Against Antiviral Resistant H1N1 | www.medicalnewstoday.com

All 3 of these drugs are approved for use. Rimantadine is usually interchangeable with amantadine and is less toxic. Ribavirin can have very nasty side effects. Not clear from the report is whether the company is marketing a use of all 3 drugs or whether they are packaging the 3 in one pill. It isa...

Peter Bornstein, MDPartner and Consultant in Infectious DiseasesSt. Paul Infectious Disease Associates, Ltd

The good news is that these drugs are already approved

October 28, 2009

Analysis of:  Triple-combo Drug Shows Promise Against Antiviral Resistant H1N1 | www.medicalnewstoday.com

Adamas has a proprietary mixture of three drugs: amantadine, oseltamivir and ribavirin to treat antiviral resistant strains of novel H1N1 Influenza A.

Flu Emergency Calls for all Alternatives to be Considered

October 27, 2009

Analysis by:GLG Expert Contributor

Analysis of:  Sinovac Biotech gets approval to distribute swine flu vaccine Panflu in Mexico | www.pharmabiz.com

H1N1 is a deadly strain of flu that has caused the White House to declare an emergency. The CDC says that instead of having 40 million doses of vaccines available there are only 28 - 30 million. On Friday an anti-viral was given emergency use authorization which allows it to be used even though itis...

Jeffrey WeinbergDirector of Clinical Research - DermatologyST LUKE'S-ROOSEVELT HOSPITAL CENTER

Starpharma gets US patent for use of VivaGel for protection against STIs

September 29, 2009

Analysis of:  Starpharma gets US patent for use of VivaGel for protection against STIs | www.pharmabiz.com

Starpharma's lead product, is a vaginal microbicide gel under development for the prevention of sexually transmitted infections (STIs), including genital herpes and HIV infection. The VivaGel® product concept is designed to offer a safe, convenient and affordable means for women to protect themselves...

Frank Malinoski, MD, PhDPresidentTD Consultancy, LLC

HIV: One Step Closer, but...

September 25, 2009

Analysis of:  Sanofi Pasteur Commends Results of First HIV Vaccine Study to Show Some Effectiveness in Preventing HIV | www.pipelinereview.com

This is the first proof of concept that some protection can be achieved with a complex vaccine schedule using two products in prime-boost (sanofi-pasteur (EURONEXT: SAN and NYSE: SNY)and Global Solutions for Infectious Diseases with ties to VaxGen (OTCBB   VXGN)).This will not be a product...

Frank Malinoski, MD, PhDPresidentTD Consultancy, LLC

Four of Five H1N1 Vaccines Approved

September 16, 2009

Analysis of:  FDA Approves Vaccines for 2009 H1N1 Influenza Virus Approval Provides Important Tool to Fight Pandemic | www.fda.gov

Four manufacturers have received approval for their H1N1 vaccines: CSL, MedImmune, Novartis, and sanofi-pasteur.FDA confirms single dose at 15 ug for injectable vaccine and standard dose for LAIV is adequate with robust immune responses.Testing in pediatrics not yet complete.GSK was not among those...

Frank Malinoski, MD, PhDPresidentTD Consultancy, LLC

A September to Watch-- and Remember: H1N1 Vaccine 1st Tipping Point Positive

September 11, 2009

Analysis of:  Response After One Dose of Monovalent Influenza A (H1N1) Vaccine-- Preliminary Report | content.nejm.org

 The Southern Hemisphere influenza season showing H1N1 declining to "normal" levels (WHO release 11 Sep 09 CSL published data on their egg based subunit vaccine with over 90% response rate to the 15 ug (standard) dose. Accompanying article with similar positive results with adjuvant by Novartis. If...

Can we trust Sinovac swine flu results?

September 9, 2009

Analysis by:GLG Expert Contributor

Analysis of:  Sinovac gets Chinese government's order to supply H1N1 vaccine | www.pharmabiz.com

The quoted dates for Sinovac's vaccine development sound too god to be true The clinical trial was commenced just 5 weeks after vaccine production started - how was quality control fitted into this The Chinese govt who desperately need >1 billion doses of swine flu vaccine to prevent a national...

Hopes in Swine Flu Vaccine

August 23, 2009

Analysis by:GLG Expert Contributor

Analysis of:  Sinovac Reports Top-Line Preliminary Results of H1NI Vaccine Clinical Trials | www.pipelinereview.com

H1N1 Swine Flu Infection is a global pandemic now,for which vaccine is an important need for a mankind to protect people from dying in whole world,but the problem is that this is a viral infection of Upper respiratory like other flu viruses,it also mutates in seconds making the H1 N1 vaccine ineff...

Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 362